• Explore /
  • Poster
  • / <span>The role of sabizabulin in phase 1b/2 clinical trials of men with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting agents.</span>

The role of sabizabulin in phase 1b/2 clinical trials of men with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting agents.

Abstract Poster

Authors

null

Mark Christopher Markowski

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Mark Christopher Markowski , Mario A. Eisenberger , Christopher Michael Pieczonka , Robert H. Getzenberg , Domingo Rodriguez , K. Gary Barnette , Mitchell S. Steiner , Daniel R. Saltzstein , Emmanuel S. Antonarakis , Ronald F. Tutrone

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03752099

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 110)

DOI

10.1200/JCO.2022.40.6_suppl.110

Abstract #

110

Poster Bd #

P5

Abstract Disclosures

Similar Posters

First Author: Mark Christopher Markowski

First Author: Mark Christopher Markowski

First Author: Sumit Kumar Subudhi

First Author: Mark Christopher Markowski